Hemostasis Today

May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Prashant Chandra: Managing Cardiovascular Risk Through Homocysteine Reduction
May 4, 2026, 15:57

Prashant Chandra: Managing Cardiovascular Risk Through Homocysteine Reduction

Prashant Chandra, Assistant Professor at Amrita School of Pharmacy, shared a post on LinkedIn:

“In this video, I explain the treatment of homocysteinemia using Vitamin B-complex therapy – specifically Vitamin B6 (Pyridoxine), Vitamin B9 (Folic Acid), and Vitamin B12 (Cobalamin).

I begin by simplifying the biochemical pathway of methionine metabolism:

  • Methionine is converted into homocysteine.
  • Homocysteine can either be remethylated back to methionine (requires Vitamin B12 and Folic Acid)
  • Or converted into cysteine via the trans-sulfuration pathway (requires Vitamin B6).

When these vitamins are deficient, homocysteine accumulates in the blood, leading to hyperhomocysteinemia.

Elevated homocysteine levels are associated with:

  • Endothelial dysfunction
  • Oxidative stress
  • Increased risk of thrombosis
  • Higher chances of Myocardial Infarction (MI) and stroke

This video clearly explains:

  • The underlying pathophysiology
  • Why Vitamin B6, B9, and B12 are prescribed together
  • How correcting deficiencies helps reduce vascular risk
  • Clinical relevance in cardiovascular prevention

If any specific brands of Vitamin B-complex capsules are mentioned in the video, they are cited purely for educational and illustrative purposes and not for promotional intent.

This content is intended for educational awareness and better understanding of cardiovascular risk management.”

Stay updated with Hemostasis Today.